Prognostic Value of the C-reactive Protein-to-Lymphocyte Ratio (CLR) for Lupus Nephritis: Comparison With Neutrophil-to-Lymphocyte Ratio (NLR) and Fibrinogen-to-Albumin Ratio (FAR)

C反应蛋白与淋巴细胞比值(CLR)对狼疮性肾炎的预后价值:与中性粒细胞与淋巴细胞比值(NLR)和纤维蛋白原与白蛋白比值(FAR)的比较

阅读:1

Abstract

Background This study aimed to evaluate the prognostic value of C-reactive protein-to-lymphocyte ratio (CLR) in lupus nephritis (LN), and compare its utility with neutrophil-to-lymphocyte ratio (NLR) and fibrinogen-to-albumin ratio (FAR). Methods We retrospectively enrolled 359 newly diagnosed or immunosuppressant-free LN patients, including 215 with renal biopsy data. A composite endpoint was used to define poor renal prognosis. Baseline CLR, NLR, and FAR at first hospitalization were compared between patients with and without poor prognosis, and their correlations with clinical characteristics were analyzed. Prognostic value was assessed using receiver operating characteristic (ROC) analysis, Kaplan-Meier survival analysis, and least absolute shrinkage and selection operator (LASSO) Cox regression. Results Over a median follow-up of 36 months, 137 patients reached the composite endpoint. Baseline CLR, NLR, and FAR were significantly elevated in the endpoint group. CLR exhibited the strongest correlation with disease activity (SLEDAI) compared to NLR and FAR, and correlated significantly with active pathological lesions (activity index, endocapillary hypercellularity). The area under the ROC curve (AUC) for CLR in predicting poor prognosis was 85.94%, significantly higher than that of NLR or FAR. Patients with CLR >2.23 (optimal cut-off) had significantly poorer renal outcomes. LASSO Cox regression identified CLR as an independent predictor of poor renal prognosis, regardless of whether pathological parameters were included. Conclusion CLR demonstrates superior prognostic value for renal outcomes in LN compared to NLR and FAR. Its strong association with disease activity and pathological findings suggests CLR may serve as a valuable, readily available early warning biomarker in clinical practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。